224 related articles for article (PubMed ID: 22282219)
21. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
Picus J; Halabi S; Kelly WK; Vogelzang NJ; Whang YE; Kaplan EB; Stadler WM; Small EJ;
Cancer; 2011 Feb; 117(3):526-33. PubMed ID: 20862750
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer.
Garzotto M; Myrthue A; Higano CS; Beer TM
Urol Oncol; 2006; 24(3):254-9. PubMed ID: 16678060
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Naito S; Tsukamoto T; Koga H; Harabayashi T; Sumiyoshi Y; Hoshi S; Akaza H
Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
[TBL] [Abstract][Full Text] [Related]
25. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer.
Narita S; Tsuchiya N; Kumazawa T; Maita S; Numakura K; Obara T; Tsuruta H; Saito M; Inoue T; Horikawa Y; Satoh S; Nanjyo H; Habuchi T
World J Surg Oncol; 2012 Jan; 10():1. PubMed ID: 22214417
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
Nosov A; Reva S; Petrov S; Mamijev E; Novikov R; Veliev E; Imkamp F; Tolkach Y; Moiseenko V
Prostate; 2016 Nov; 76(15):1345-52. PubMed ID: 26864707
[TBL] [Abstract][Full Text] [Related]
27. Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905).
Kim HR; Jung KH; Im SA; Im YH; Kang SY; Park KH; Lee S; Kim SB; Lee KH; Ahn JS; Kim SI; Sohn JH
Ann Oncol; 2013 Jun; 24(6):1485-90. PubMed ID: 23380385
[TBL] [Abstract][Full Text] [Related]
28. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Shepard DR; Dreicer R; Garcia J; Elson P; Magi-Galluzzi C; Raghavan D; Stephenson AJ; Klein EA
J Urol; 2009 Apr; 181(4):1672-7; discussion 1677. PubMed ID: 19230915
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Friedman J; Dunn RL; Wood D; Vaishampayan U; Wu A; Bradley D; Montie J; Sarkar FH; Shah RB; Hussain M
J Urol; 2008 Mar; 179(3):911-5; discussion 915-6. PubMed ID: 18207190
[TBL] [Abstract][Full Text] [Related]
31. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
Thalgott M; Horn T; Heck MM; Maurer T; Eiber M; Retz M; Autenrieth M; Herkommer K; Krause BJ; Gschwend JE; Treiber U; Kübler HR
J Hematol Oncol; 2014 Mar; 7():20. PubMed ID: 24598155
[TBL] [Abstract][Full Text] [Related]
33. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
34. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz B; Schnall M; Schultz D; Cote K; Tomaszewski JE; Wein A
J Urol; 2000 Sep; 164(3 Pt 1):759-63. PubMed ID: 10953141
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
Beer TM; Garzotto M; Lowe BA; Ellis WJ; Montalto MA; Lange PH; Higano CS
Clin Cancer Res; 2004 Feb; 10(4):1306-11. PubMed ID: 14977829
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.
Mathew P; Pisters LL; Wood CG; Papadopoulos JN; Williams DL; Thall PF; Wen S; Horne E; Oborn CJ; Langley R; Fidler IJ; Pettaway CA
J Urol; 2009 Jan; 181(1):81-7; discussion 87. PubMed ID: 19012911
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Armstrong AJ; Halabi S; Healy P; Lee WR; Koontz BF; Moul JW; Mundy K; Creel P; Wood S; Davis K; Carducci MA; Stein M; Hobbs C; Reimer B; Nguyen M; Anand M; Bratt L; Kim S; Tran PT; George DJ;
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):100-6. PubMed ID: 26754260
[TBL] [Abstract][Full Text] [Related]
39. Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
Blanchard P; Faivre L; Lesaunier F; Salem N; Mesgouez-Nebout N; Deniau-Alexandre E; Rolland F; Ferrero JM; Houédé N; Mourey L; Théodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Davin JL; Habibian M; Culine S; Laplanche A; Fizazi K
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):85-92. PubMed ID: 26576711
[TBL] [Abstract][Full Text] [Related]
40. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer.
D'Amico AV; Whittington R; Malkowicz SB; Wu YH; Chen M; Art M; Tomaszewski JE; Wein A
Urology; 2000 Apr; 55(4):572-7. PubMed ID: 10736506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
